Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Internal Medicine Alert

RSS  

Articles

  • Clinical Briefs by Louis Kuritzky, MD

    Because the consequence of missed pulmonary embolism (PEM) is so grave, it is essential to continue our evolution of tools which maximize diagnostic sensitivity, offer clinical expedience, and minimize risk for the patient.
  • Regadenoson Injection (Lexiscan™)

    Regadenoson, the first selective A2A adenosine receptor agonist, has been approved for use as a pharmacologic stress agent for nuclear medicine stress testing (radionuclide myocardial perfusion imaging).
  • LDL Lowering - Should Ezetimibe Ever Be Used?

    Lifestyle changes such as improving diet and exercise are always the first important approach for the treatment of hyperlipidemia however, if the target LDL-C level is not achieved using statins and niacin, fibrates, and/or resins, at this time, ezetimibe should definitely be utilized to achieve these target goals if there are no specific contraindications to the use of the drug in each individual patient.
  • Certolizumab Pegol Injection (Cimzia®)

    Another monoclonal antibody to TNF-a has been approved for the treatment of Crohn's Disease.
  • Viral Influenza Complications

    Clinicians are becoming more attuned to the many complications of influenza, particularly with the high morbidity and mortality seen with H5N1 strains spreading around the world.
  • Clinical Briefs by Louis Kuritzky, MD

    In 2007, the ACCF/AHA published a consensus statement in the Journal of the American College of Cardiology endorsing a role for coronary artery calcium scoring (CAC) in cardiovascular risk stratification.
  • Ten-Year Update on AAAs

    One-time screening for abdominal aortic Aneurysms (AAA) is recommended in older men, but there is little long-term data on the value of such screening, especially in women.
  • So You Took Hormones, Now What?

    For those women who were randomized to estrogen plus progesterone in the Women's Health Initiative Trial, the increased risk of breast cancer has persisted since stopping the replacement therapy, but the increased risk of cardiovascular events has returned to that of the placebo group.
  • Clinical Briefs by Louis Kuritzky, MD

    Coronary artery disease (CAD) is the most common cause of death in America, and diabetics suffer a disproportionate burden of risk from cardiovascular disease.
  • Should We Be Screening for Hepatitis C?

    Among veterans with risk factors for hepatitis C, a screening program yields results of limited value. The number needed to screen to yield a treatable case of hepatitis C was 451, but the number needed to screen for a successful outcome was more than 4000.